More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment. But experts say access is still limited, and more research on its long-term safety in teens is needed, NBC News reported. Prescriptions of Wegovy to teens rose 50% in 2024, according to Truveta, a health data company. The drug was prescribed to 14.8 of every 100,000 adolescents, up from 9.9 in 2023. Wegovy was approved in late 2022 for kids 12 and older who struggle with obesity. In the first three months of 2025, the rate rose again — to 17.3 prescriptions per 100,000 teens. Still, that’s tiny fraction of the U.S. teens who are living with obesity. “It’s promising that more young people are using these medications, but it’s still a very small percentage of patients with severe obesity that are getting access to them,” Dr. Cate Varney, an obesity medicine specialist at the University of Virginia Health System, told NBC News. “When lifestyle changes alone are insufficient, we need these additional tools.” Truveta reviewed the health records of 1.3 million 12- to 17-year-olds. The data included 30 U.S. health systems, with more than 900 hospitals and 20,000 clinics. The study looked only at Wegovy, not other GLP-1 drugs like Ozempic or Zepbound, which are not approved for teen weight loss. About 8 million U.S.… read on > read on >

















